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Objectives
The Dolutegravir Monotherapy for HIV (DOMONO; NCT02401828) study showed that maintenance
monotherapy with dolutegravir (DTG) is associated with virological failure (VF) and leads to DTG
resistance and as a result should not be used. However, data on clinical and virological factors
associated with VF during DTG monotherapy are lacking. We identified factors associated with VF
during DTG monotherapy.
Methods
A randomized trial was carried out in which patients on combination antiretroviral therapy (cART)
with an HIV-1 RNA zenith < 100 000 copies/mL and a CD4 T-cell nadir ≥ 200 cells/lL, who had
never experienced VF, switched to DTG monotherapy. Clinical and virological factors were
compared between patients with and without VF, using univariate analyses.
Results
Eight of the 95 patients developed VF during DTG monotherapy. A total of 78 participants had
reached week 48 when the study was discontinued. The median CD4 T-cell nadir was lower in
patients with VF than in patients without VF [260 (interquartile range (IQR) 223–320) versus 380
(IQR 290–520) cells/lL, respectively; P = 0.011]. Patients with VF had a longer time between HIV
diagnosis and cART initiation than those without VF [median 49 (IQR 27–64) versus 15 (IQR 1–
38) months, respectively; P = 0.015]. The median total peripheral blood mononuclear cell (PBMC)
HIV DNA copy number was higher in patients with VF than in those without VF [417 (range 85–
4151) versus 147 (range 16–4132) copies/106 PBMCs, respectively; P = 0.022].
Conclusions
A lower CD4 nadir, a longer time between HIV diagnosis and cART initiation, and a higher HIV
DNA copy number at the time of DTG monotherapy initiation were associated with VF. While there
clearly is no future role for DTG monotherapy, ongoing and future studies on the efficacy of
maintenance dual therapy (e.g. DTG lamivudine) may have to take these variables into account in
their study design and analysis.
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SHORT COMMUNICATION
Introduction
Dolutegravir (DTG)-based combination antiretroviral ther-
apy (cART) is one of the preferred treatment options in cur-
rent guidelines for HIV-1 treatment. Given the high genetic
barrier of DTG maintenance monotherapy to resistance
based on previously determined in vitro data [1–5], we
studied its efficacy in the Dolutegravir Monotherapy for
HIV (DOMONO; NCT02401828) study [6]. In DOMONO, 95
virologically suppressed patients on cART, selected on
strict criteria regarding CD4 T-cell nadir and HIV RNA
zenith, started DTG monotherapy. The study was discontin-
ued prematurely, because virological failure (VF) was
observed in eight patients, of whom three had integrase
inhibitor resistance-associated mutations [6–8]. Previous
studies on protease inhibitor (PI) maintenance monother-
apy identified time on cART, drug adherence during
monotherapy, the presence of very low level viraemia
(< 50 HIV-1 RNA copies/mL) at baseline and CD4 T-cell
nadir as predictors of failure [9,10]. Additionally, the
peripheral blood mononuclear cell (PBMC) HIV DNA copy
number was associated with the risk of VF in the MONOI
study and PROTEA study [9,11]. Predictors of VF during
integrase inhibitor monotherapy have not been described.
Here, we determined which clinical and virological factors
were associated with VF during DTG monotherapy.
Methods
The DOMONO study (NCT02401828) was a randomized
clinical noninferiority trial. Participants provided written
informed consent, and the study was approved by the
ethics committee (METC Erasmus MC; MEC2015-043) and
performed in accordance with the Helsinki Declaration.
Details can be found elsewhere, but, in brief, 95 patients
who were virologically suppressed on cART, had never
failed any antiretroviral regimen, and had a CD4 T-cell
nadir ≥ 200 cells/lL and an HIV RNA zenith
< 100 000 copies/mL consented to switch from cART to
DTG monotherapy [6]. The primary outcome of this study
was virological suppression at week 24 during DTG
monotherapy, and we defined VF as a confirmed plasma
HIV RNA > 200 copies/mL. Clinical and virological factors
were compared between patients with and without VF
using unpaired t-tests, Mann–Whitney U-tests, and Fisher’s
exact tests, when applicable. As a consequence of the rela-
tively low number of patients with VF at the time when the
study was discontinued, a multivariable analysis could not
be performed. Factors included were as follows: age, sex,
the pre-cART HIV RNA zenith and CD4 T-cell nadir, the
CD4 T-cell count at the start of DTG monotherapy, and the
time between HIV diagnosis and cART initiation. Other
evaluated factors were the type of cART regimen before the
switch to DTG monotherapy (nonnucleoside reverse tran-
scriptase inhibitor- versus PI- versus integrase strand
transfer inhibitor-containing cART), the time on cART,
whether the patient had a detectable viral load at the start
of DTG monotherapy (defined as an HIV plasma viral load
of > 20 copies/mL or an HIV plasma viral load that was
detectable but < 20 copies/mL), DTG plasma concentra-
tion, and the total HIV DNA copy number in PBMCs at the
start of DTG monotherapy. Total HIV DNA quantification
was performed by droplet digital polymerase chain reac-
tion (ddPCR), as described elsewhere, and could be carried
out in 77 patients (eight patients with VF and 69 without
VF) from whom PBMCs had been successfully harvested
[12–14].
Results
A total of Seventy-eight of the 95 participants had
reached the week 48 endpoint when the study was dis-
continued prematurely in accordance with one of the pre-
defined stopping rules. At the time of study
discontinuation, VF had been observed in eight patients.
The median follow-up duration was 59 [interquartile
range (IQR) 48–71] weeks and for 17 patients, including
five with VF, the follow-up was < 48 weeks. The charac-
teristics of the patients with and without VF are described
in Table 1. According to the inclusion criteria the median
HIV RNA zenith was low and the median CD4 T-cell
nadir was relatively high with a minimum of 200 cells/
lL. The median CD4 T-cell nadir was significantly lower
in patients with VF [260 (IQR 223–320) cells/lL] than in
those without VF [380 (IQR 290–520) cells/lL]
(P = 0.011). Also, the median time between HIV diagnosis
and cART initiation was longer in patients with VF: 49
(IQR 27–64) months versus 15 (1–38) months for patients
without VF on DTG monotherapy (P = 0.015). At the start
of DTG monotherapy, no significant differences were
observed between patients with and without VF regarding
the number of patients with detectable plasma HIV RNA,
the CD4 T-cell count, the CD4:CD8 ratio, or the C-reactive
protein (CRP) concentration. In contrast, the median total
HIV DNA copy number in PBMCs at the time of DTG
monotherapy initiation differed significantly between the
two groups: 147 (range 16–4132) versus 417 (range 85–
4151) copies per 106 PBMCs in those without and with
VF, respectively (P = 0.022). DTG plasma levels were ade-
quate (i.e. > 0.1 mg/L) in all patients with VF, and no dif-
ference in median DTG plasma concentration was
observed between the patients with VF and 20 randomly
selected patients without VF: 1.70 (range 0.70–2.90) mg/L
versus 1.65 (range 0.70–4.50) mg/L, respectively. See
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Figure 1 for boxplots of CD4 T-cell nadir, time between
HIV diagnosis and start of cART, total HIV DNA copy
number in PBMCs and DTG plasma concentration in
patients with and without VF.
Discussion
In the DOMONO study, we clearly showed that DTG
maintenance monotherapy is associated with VF and the
development of DTG resistance and should not be used as
maintenance monotherapy. In the current study, we eval-
uated potential predictors of VF during integrase inhibitor
monotherapy. We showed that a higher cell-associated
total HIV DNA copy number at the start of monotherapy,
a lower CD4 T-cell count nadir, and a longer time
between HIV diagnosis and start of cART were signifi-
cantly associated with VF. A lower CD4 T-cell count
nadir and a higher cell-associated HIV DNA copy number
have previously also been described as risk factors for
virological failure during PI monotherapy [9–11]. In con-
trast, none of the following ten factors were associated
with VF during DTG monotherapy: gender, age, CD4 T-
cell count, CRP concentration, CD4:CD8 ratio, type of
cART regimen, whether the patient had detectable plasma
HIV RNA (all at the time of DTG monotherapy initiation),
DTG plasma concentrations during monotherapy, the
duration of viral suppression on cART, and the HIV RNA
zenith before DTG monotherapy initiation. Also, no
differences were observed in plasma viral load detectabil-
ity in the 12 months preceding DTG monotherapy initia-
tion: three of 87 patients without VF versus zero of eight
patients with VF had HIV RNA > 20 copies/mL in the
12 months preceding the switch to DTG monotherapy.
Various PI monotherapy studies identified suboptimal
adherence as a risk factor for VF [9,15,16]. We were unable
to analyse adherence as a predictor of VF because the inclu-
sion and exclusion criteria of the study led to the selection
of a very therapy-adherent study population: no history of
VF on any previous cART regimen, self-reported adherence
during DTG monotherapy > 95%, and therapeutic DTG
plasma concentrations in all patients with and without VF.
DTG plasma concentrations were adequate in both groups,
and there was no significant difference in DTG plasma con-
centration between patients with and without VF, which is
consistent with previous studies which did not identify
lower PI plasma concentrations as a risk factor for VF in
patients receiving PI monotherapy [16,17]. It must be noted
that drug level measurement was only performed at single
time-points, so the possibility of temporary nonadherence
between study visits cannot be ruled out.
A limiting factor of this study is the relatively small
number of patients who experienced VF in comparison to
the above-mentioned PI studies. Even if we had consid-
ered an isolated and unconfirmed viral load > 50 copies/
mL as VF (as observed in 14 patients), the number of
patients with VF would have been too small to enable a
Table 1 Baseline characteristics of patients with and without virological failure (VF) during dolutegravir (DTG) maintenance monotherapy,
including P-values for the univariate analysis
No VF during DTG monotherapy
(n = 87)




Age (years) [mean (SD)] 47 (11.0) 47 (11.2) 0.891 (UTT)
Male sex [n (%)] 80 (92) 8 (100) 1.00 (FET)
HIV RNA zenith (copies/mL) 37000 (12 950, 65 625) 27350 (17 750, 64 325) 0.973 (MWU)
Residual Viraemia at start of DTG* [n (%)] 10 (11.5) 2 (25.0) 0.266 (FET)
HIV DNA (copies/106 PBMCs) 147 (69, 338) 417 (181, 837) 0.022 (MWU)
Log10 HIV DNA (log10 copies/10
6 PBMCs) [mean (SD)] 2.16 (0.53) 2.57 (0.40) 0.037 (UTT)
CD4 T-cell nadir (cells/lL) 380 (290, 520) 260 (223, 320) 0.011 (MWU)
CD4 T-cell count at start of DTG (cells/lL) 650 (540, 825) 830 (573, 1030) 0.153 (MWU)
CD4:CD8 ratio at start of DTG 1.05 (0.74, 1.50) 1.41 (0.74, 2.00) 0.507 (MWU)
C-reactive protein at start of DTG (mg/L) 1.20 (0.40, 2.70) 1.45 (0.73, 3.08) 0.673 (MWU)
DTG plasma concentration (mg/L) 1.65 (1.23, 3.75) 1.70 (1.05, 2.40) 0.308 (MWU)
% deviation of DTG plasma concentration from population
average
12.9 (43.2, 55.2) 10.9 (27.6, 45.5) 0.879 (MWU)
cART before DTG [n (%)]
NNRTI 69 (79.3) 7 (87.5) 0.783 (CST)
PI 4 (4.6) 0 (0)
INI 14 (16.1) 1 (12.5)
Time between HIV diagnosis and start of cART (months) 15 (1, 38) 49 (27, 64) 0.015 (MWU)
Time suppressed on cART (months) 31 (20, 54) 57 (28, 94) 0.104 (MWU)
Data shown are median (Q1, Q3), unless otherwise stated.
SD, standard deviation; UTT, unpaired t-test; FET, Fisher’s exact test; MWU, Mann–Whitney U-test; PBMCs, peripheral blood mononuclear cells; cART,
combination antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INI, integrase inhibitor; CST, v2 test.
*Residual viraemia is defined as HIV RNA detectable but < 20 copies/mL or HIV RNA > 20 copies/mL.
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multivariate analysis to be performed. Therefore, we were
not able to assess whether CD4 T-cell count nadir, time
between HIV diagnosis and start of cART, and cell-asso-
ciated HIV DNA level are independent risk factors for VF
during DTG maintenance monotherapy. Actually, CD4
T-cell count nadir, time between HIV diagnosis and start
of cART, and cell-associated HIV DNA level could very
well be correlated. Indeed, Boulassel et al. [18] previously
showed that there was an inverse relationship between
CD4 T-cell nadir and cell-associated HIV DNA level, and
that a longer time between HIV diagnosis and start of
cART was associated with higher cell-associated HIV
DNA level [19]. This implies that the size of the viral
reservoir is probably the most important determinant of
VF, as the cell-associated total HIV DNA level is a mea-
sure of the size of the viral reservoir in virologically sup-
pressed patients. The reactivation of HIV from latently
infected cells is a stochastic process, which occurs on
average every 5–8 days, and depends on the size of the
replication-competent viral reservoir [20]. Our observa-
tion that a higher HIV DNA level was associated with VF
is in agreement with stochastic reactivation of pre-exist-
ing provirus harbouring a single mutation associated with
integrase inhibitor resistance. It would have been useful
to provide data on the size of the reservoir at the time of
VF. Unfortunately, we did not collect PBMCs at the time
of VF, and therefore we are not able to provide these
data.
In conclusion, a longer time between HIV diagnosis
and cART initiation, a lower CD4 count nadir, and a
higher total HIV DNA copy number increased the risk of
VF during DTG monotherapy. While there clearly is no
future role for DTG monotherapy, ongoing and future
studies on the efficacy of maintenance dual therapy (e.g.
DTG with lamivudine) should take these variables into
account in their study design and analysis.
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